Meta-analysis reveals hyperferritinemia indicates severe metabolic dysfunction in MASLD, suggesting risk stratification.
HF is present in approximately one in four patients with MASLD and identifies a subgroup with more severe metabolic dysfunction and liver injury. These data highlight SF as a simple, accessible biomarker that may help identify higher-risk MASLD phenotypes.
No takes yet. Share an insight, caveat, or question.
Souza et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: